Recent studies have suggested that HIV-1 infectivity may be highest early after HIV-1 acquisition. In one prospective study, the risk of transmission to a sexual partner during the first 2.5 months after HIV-1 seroconversion was nearly 12-fold higher than during chronic infection [1] . It has therefore been suggested that early HIV-1 infection may play a dominant role in epidemic HIV-1 spread [2] . Early HIV-1 infection is characterized by high levels of systemic viral replication, but there is little information on the levels of genital HIV-1 at that time, which may be more relevant to infectivity. Here, we aimed to investigate HIV-1-RNA levels in the female genital tract during early HIV-1 infection.
Between 1993 and 2003, we enrolled HIV-1-seronegative female sex workers in Mombasa, Kenya, in a prospective cohort study of HIV-1 acquisition [3] . At approximately monthly visits, HIV-1 and sexually transmitted infection (STI) screening was performed. If HIV-1 seroconversion had occurred, plasma and a cervical specimen were collected by gently inserting a swab 1 cm into the cervical os and rotating two full turns. Plasma and cervical swabs were collected approximately quarterly thereafter. HIV-1 RNA was measured using the Gen-Probe HIV-1 viral load assay and lower limits of quantification of 100 copies/ml plasma and 50 copies per swab were applied [3, 4] . Informed consent was obtained from all participants. The study was approved by the ethical review committees of the University of Nairobi, the University of Washington, and the Fred Hutchinson Cancer Research Center.
A combination of HIV-1 serological and plasma RNA data were used to estimate dates of HIV-1 acquisition, as previously described [3] . For this analysis, we selected all women who had a set of plasma and cervical samples from within 90 days of infection and another plasma/cervical set from 4-24 months after infection, after the establishment of steady-state systemic viral replication (known as viral setpoint). Each woman thus served as her own control. If more than one setpoint measurement was available, the first was used.
A total of 60 women met these criteria: 11 whose early visits were within 30 days of HIV-1 acquisition, 23 whose early visits were 31-60 days after HIV-1 acquisition, and 26 whose early visits were 61-90 days after HIV-1 acquisition. Setpoint samples were collected at a median of 194 days (interquartile range 156-260) after HIV-1 acquisition. There were no statistically significant differences in the timing of setpoint samples among the three study groups. The median age was 30 years (interquartile range 26-35).
Cervical HIV-1-RNA levels were significantly higher in early samples compared with setpoint samples (mean 3.43 versus 2.85 log 10 copies/swab, respectively, P < 0.001, paired samples t-test). Generalized estimating equations were used to compare early with setpoint cervical HIV-1-RNA levels (see Table 1 ). In unadjusted analysis, the difference between early and setpoint cervical HIV-1 RNA decreased in a step-wise fashion with increasing time from HIV-1 acquisition: by 0.89 log 10 copies per swab for within 30 days (P < 0.001), by 0.53 log 10 copies per swab for 31-60 days (P ¼ 0.02), and by 0.49 log 10 copies per swab for 61-90 days (P ¼ 0.02). The magnitude of these coefficients decreased when adjusted for the HIV-1 plasma viral load, suggesting that much of the difference was associated with higher systemic viral replication during early infection. However, a difference of 0.68 log 10 copies per swab between early and setpoint viral levels remained after adjustment for plasma viral load for women whose early samples were collected within 30 days of infection. An additional multivariate model was constructed, further adjusting for the presence of a cervical STI, which has been associated with increased genital HIV-1 replication [4] . In this model, samples from within 30 days of HIV-1 acquisition retained increased cervical RNA levels (by 0.45 log 10 copies per swab, P ¼ 0.006). The HIV-1 plasma viral load and cervical STI were also independently associated with significantly higher cervical HIV-1-RNA levels.
There has been considerable recent interest in the contribution of early HIV-1 infection to sexual HIV-1 transmission dynamics [2] , but very few studies on the presence of virus in the female genital tract during early HIV-1 infection have been conducted. To our knowledge, the largest study included only two women [5] . Therefore, the data presented here are the first to characterize a key marker of early HIV-1 infectivity in women.
The genital tract viral load was highest in the first month post-infection, and then gradually decreased, a pattern similar to that observed for plasma viral replication. Studies of individuals with chronic HIV-1 infection have generally found that plasma viral load is the strongest predictor of genital HIV-1 concentrations. In this study, however, cervical viral levels during the first month after infection were higher than predicted by the plasma virus load, suggesting that the female genital tract may to some degree be a compartment for independent early virus replication.
In conclusion, the first months after HIV-1 acquisition are probably a time of high infectivity, perhaps especially during the first 30 days, when genital HIV-1-RNA levels may be enhanced beyond what is expected based on systemic viral replication. As has been observed during chronic HIV-1 infection, genital HIV-1 levels during early HIV-1 infection are also increased by the presence of STI. Efforts to identify, counsel, and potentially treat individuals with acute HIV-1 infection, including treatment for concurrent STI, might have significant public health effects on HIV-1 transmission. The study included all HIV patients who were at least 16 years old and were followed for at least one year after HAARTwas started at Seoul National University Hospital between January 1998 and December 2004. The hospital is a 1600-bed, university-affiliated teaching hospital and is the largest referral centre for HIV/AIDS in South Korea.
HAART is defined as the use of at least three antiretroviral drugs, including protease inhibitors or non-nucleoside reverse transcriptase inhibitors. Baseline CD4 lymphocyte counts and HIV-RNA levels were the test results obtained closest to the time of HAART initiation.
OI that developed during one year after HAART were classified as IRIS or non-IRIS. The diagnosis of IRIS was based on the previously published definition [4] . In brief, an IRIS event was defined as either a first presentation or a paradoxical worsening of a pre-existing infection after the initiation of HAART in the presence of a rising CD4 cell count and a falling HIV-1-RNA level, if measured. The agreement of two investigators was required for a diagnosis of IRIS.
For each patient with IRIS OI, two control patients without OI (OI-free group) were selected by matching age, sex, clinical category, and the baseline CD4 cell count. AIDS-defining event-free survival was compared among the groups by Kaplan-Meier survival analyses (log rank test), and adjusted hazard ratios were estimated using Cox's proportional hazards regression model. AIDSdefining illness and clinical categories were defined using 1993 Centers for Disease Control and Prevention classification criteria; diagnoses of AIDS-defining illness based on absolute CD4 lymphocyte counts less than 200 cells/ml were excluded [5] . Categorical variables were compared using Fisher's exact tests and continuous variables using the Mann-Whitney U-test. Statistical analyses were performed with SPSS software (version 12.0; SPSS Inc., Chicago, Illinois, USA). All significance tests were two-sided.
In 45 of 387 HIV patients (12%) 52 OI were identified. Of these, 33 IRIS events occurred in 31 patients; however, four of these 31 patients also experienced a non-IRIS OI and were ultimately classified into the non-IRIS group. The IRIS group thus consisted of 27 of the original 45 patients and the non-IRIS group consisted of 18 patients, four of whom had both IRIS and non-IRIS OI.
In the IRIS group, the median age was 42 years [interquartile range (IQR) 35-45] and 96% were male. Before HAART, five of the IRIS group (19%) had undergone antiretroviral treatment, and 24 (89%) had a diagnosis of AIDS. Nine patients (33%) were classified as clinical category A and 18 (67%) as clinical category C at the start of HAART.
There was no significant difference in age (P ¼ 0.89), previous history of antiretroviral treatment (P ¼ 0.67), or diagnosis of AIDS (P ¼ 1.00) between IRIS and non-IRIS groups. In the IRIS group, the most common OI was tuberculosis (27%) followed by herpes zoster (24%) and Pneumocystis jiroveci pneumonia (15%), whereas in the non-IRIS group, cytomegalovirus infection (26%) and herpes zoster (26%) were most common, followed by tuberculosis (11%).
The median baseline CD4 cell count (ml) was 43 ( At one year after the initiation of HAART, the median baseline CD4 cell count (ml) was 85 (IQR 35-189) for the non-IRIS group (P < 0.01) and 260 (IQR 220-370) for the OI-free group (P ¼ 0.74) in contrast with 285 (IQR 200-375) for the IRIS group. The viral titre was undetectable for 50% of the patients in the non-IRIS group (P ¼ 0.14) and 67% in the OI-free group (P ¼ 0.39) compared with 78% in the IRIS group.
There was a median follow-up duration of 3.1 years (IQR 1.9-4.6) per individual after starting HAART. Patients in the IRIS group demonstrated a significantly better outcome than patients in the non-IRIS group (P ¼ 0.007), and showed no significant difference in the AIDS event-free survival curve compared with the OI-free group (P ¼ 0.81; Fig. 1 ).
After adjusting for age, baseline CD4 cell count, the number of antiretroviral drugs experienced before beginning HAART, non-infectious AIDS-defining illness, and the number of missed clinic appointments during one year after the initiation of HAART, the hazard ratio for AIDS-defining illness or death was 3.75 [95% confidence interval (CI)1.05-13.44,P ¼ 0.04] for the non-IRIS group and 1.32 (95% CI 0.31-5.58, P ¼ 0.70) for the OI-free group contrasting with the IRIS group.
The incidence of IRIS in this study was comparable with that of previous studies. Ratnam et al. [6] reported that 23% of patients who start HAART experience an IRIS event. Michelet et al. [7] showed that 18 out of 34 clinical events (53%) observed during the first 2 months of HAARTwere thought to be IRIS. The spectrum of IRIS in the present study was largely similar to that of non-IRIS in same period as well as that of OI in the era before HAART [8] .
The clinical manifestation of IRIS may be very similar to that of non-IRIS OI [2] . However, our study found that IRIS-associated OI have an entirely different prognosis from non-IRIS OI. This difference may be explained by the fact that IRIS indicates good compliance with and a successful response to HAART. It should also be noted that in the present study, IRIS did not result in a better clinical outcome than that of OI-free patients with a similar immune defect at the start of HAART.
To evaluate the long-term clinical outcome, this study population was confined to patients who were followed for at least one year; thus it did not include cases with early mortality. However, severe IRIS cases with mortality are known to be very rare [3] .
In spite of the small case number and the retrospective nature of this study, to our knowledge this is first investigation to focus on the effect of IRIS on the longterm clinical outcome. Our results suggest that IRIS OI should be differentiated from non-IRIS OI because patients with IRIS have a significantly different prognosis. 325 per year, which represents only 5% (approximately 6000 cases) of all new cases diagnosed each year and only 8% of all new infections (approximately 4000 cases).
The proportion of incident cases of HIV infection that are diagnosed during the primary phase is not known, but would be a useful indicator of the capacity of healthcare systems to identify infected patients rapidly. In addition, most studies monitoring the transmission of resistant strains of HIV are based on cases diagnosed at the time of primary infection [1] [2] [3] , but it is not known whether these patients are representative of the overall infected population.
The aims of this study were to estimate the yearly number of patients diagnosed at the time of primary HIV-1 infection in France between 1999 and 2002, and to compare the characteristics of these patients with those of other patients diagnosed in the chronic stage during the same period.
The capture-recapture method consists of matching two sources of case notification in order to determine the number of common cases, and then to estimate the total number of cases (N) in the population.
The French ANRS-CO6 PRIMO cohort enrolls patients diagnosed during or soon after primary HIV-1 infection (a negative or indeterminate HIVantibody assay associated with a positive antigenemia or plasma HIV RNA, or an incomplete Western blot with an absence of antibodies to pol proteins, or an initially negative test for HIV antibody followed within 6 months by a positive HIV serology), in 77 participating hospital units [4] . The date of infection was estimated as the date of symptom onset minus 15 days, or the date of an incomplete Western blot minus one month, or the midpoint between a negative and a positive enzyme-linked immunosorbent assay. The interval between the estimated date of infection and enrollment could not exceed 6 months.
The French Hospital Database on HIV (FHDH, ANRS-CO4) enrolls HIV-1-infected patients managed in 62
participating hospitals [5] . For patients with available information, the date of infection is estimated as the presumed date of infection, or the date of primary infection, or the midpoint between a negative and a positive test for HIV-1.
FHDH and PRIMO both collect data anonymously. Patients are identified by an anonymous code generated from the last name, given name, and the day and month of birth, using the same algorithm; the anonymous code can thus be used as a common identifier for record linkage [6] . For the purposes of the present study, matches were first sought on the basis of the anonymous code. In order to take into account possible errors in data entry, leading to the same patient having a different anonymous code in the two databases, matches in the remaining records were sought on the basis of sex, the month and year of birth, and the enrollment centre. The total number of patients diagnosed at the time of primary infection, N, was calculated using the Chapman estimator [7] , and an approximate unbiased estimate of the variance of N was used [8] . These estimates are valid if the following assumptions are satisfied: (i) all cases reported in each system are true cases; (ii) the matching procedure identifies all true matches and only true matches; and (iii) the data sources are independent.
We then compared the characteristics (sex, transmission group, and country of birth) of the patients diagnosed with chronic HIV-1 infection and enrolled in the FHDH less than one year after diagnosis, between 1999 and 2002, with those of patients diagnosed with primary infection. Between 1999 and 2002, the characteristics of the patients presenting with primary HIV infection differed from those of patients presenting with chronic infection during the same period (Table 1) . Male homosexual and bisexual individuals were more likely to be diagnosed at the time of primary infection, as were young patients (under 30 years) and patients born elsewhere than in subSaharan Africa.
During the period 1999-2002, the estimated number of patients diagnosed in France at the time of primary HIV-1 infection was approximately 325 per year. As concerns the application of the capture-recapture method, the source of greatest bias for the estimates is deviation from the hypothesis of independence, but this condition cannot be tested when only two sources are involved [9] . However, the fact that 38 patients in the PRIMO cohort were also enrolled in the FHDH but were not recorded as having primary infection in this latter database shows that the two sources have at worst only a small positive dependency in common centres.
Studies of the transmission of drug-resistant HIV variants use data on patients diagnosed during the primary infection. As previously underlined [3] , a major issue when interpreting the results of such studies is the lack of exhaustiveness. In France, it is estimated that at least 4000 individuals are newly infected by HIV each year [10] , but that only a small proportion are diagnosed during the primary infection, less than 10% according to our results. Another issue is whether patients diagnosed at the time of primary infection are representative, in terms of HIV resistance, of all patients infected during the same period. We found here that patients diagnosed at the time of primary infection were younger, were more often homo/ bisexual men, and were more likely to originate from France than from sub-Saharan Africa than patients diagnosed during the chronic phase. These differences are unlikely to be only explained by a recent shift in the HIV epidemic, but rather by delayed diagnosis in some subpopulations. If transmission of resistance is indeed associated with age, the transmission group or the country of origin, this would imply that patients enrolled in resistance studies during the primary infection are not representative of all newly infected patients. This should be kept in mind when interpreting studies of the transmission of resistant viruses. Forty-two pravastatin-treated HIV-positive patients and 42 sex, age, and smoking status-matched hypercholesterolemic HIV-positive patients not under lipid-lowering treatment were compared for differences in intima-media thickness (IMT) of the common carotid artery (CCA) and aortic stiffness. Pravastatin had no influence on carotid artery structure and function, or aortic stiffness. Age and body mass index were independent determinants of IMT of the CCA. Mean arterial pressure, age, duration of HIV infection and protease inhibitor exposure determined aortic stiffness.
A linear association between increased intima-media thickness (IMT) of the common carotid artery (CCA), aortic stiffness (aortic pulse wave velocity; PWV) and the incidence of cardiovascular events has been reported in the general population [1] [2] [3] [4] . The progression of IMT of the CCA has been shown to be predictive of cardiovascular events [5] . Several case-control and longitudinal studies [6] [7] [8] [9] [10] [11] [12] , with one exception [13] , have suggested that increased IMT of the CCA in HIVinfected patients receiving HAART may be associated with an acceleration of atherosclerosis compared with non-HIV-infected patients and with HIV-infected patients not on antiretroviral treatment.
To the best of our knowledge, no study to date has evaluated the effects of statin therapy on the progression of carotid atherosclerosis in dyslipidemic HIV-infected patients. We hypothesized that long-term pravastatin therapy could decrease IMT of the CCA and reduce aortic stiffness in dyslipidemic HIV-infected patients.
Patients in the pravastatin group (cases) were consecutively enrolled if they fulfilled the following criteria: (i) Two experienced technicians blinded to the patients' clinical features and treatments conducted all arterial measurements in a central core laboratory. Carotid internal diameter and IMT were measured on the right CCA at 2 cm beneath the carotid bifurcation, with a 7.5-MHz pulsed ultrasound echotracking system (Wall Track System; Pie Medical Imaging -Esaote SpA, Maastricht, the Netherlands) analysing the radiofrequency signal [7, 14, 15] . The elastic properties of the arterial wall material were estimated using Young's incremental elastic modulus calculated as previously described [4] . Aortic (carotid-femoral) PWV was measured as previously described and validated [16] .
Statistical analysis was performed using NCSS 2004 software (NCSS, Inc., Kaysville, Utah, USA). Betweengroup comparisons for quantitative variables were performed using Student's t-test or the Wilcoxon rank test according to distribution. The chi-square test was used for discrete variables. Multivariate robust regressions with stepwise selection of variables were performed to determine the relationship between arterial parameters and pravastatin therapy. Data are expressed as mean AE standard deviation. P < 0.05 was considered significant, and tests were two-sided.
Among cases, pravastatin was prescribed at a mean dose of 30 AE 10 mg/day with a mean duration of 23 AE 8 months.
(see Table 1 for the baseline characteristics of the patients). Cardiovascular risk factors were well balanced in the two groups except for body mass index, which was significantly lower among pravastatin users (22.9 AE 2.3 versus 24.1 AE 2.7, P ¼ 0.03). The duration of HIV infection and HIV treatments, the immunovirological status, and the presence of clinical lipodystrophy syndrome did not differ between the groups.
The geometrical and functional parameters of the carotid artery did not differ between the two groups and no difference in IMT in the CCA between HIV-infected patients under pravastatin and controls (689 AE 131 versus 717 AE 148 mm, P ¼ 0.36) was observed. Aortic stiffness measured using the carotid-femoral PWV did not differ between the two groups (9.6 AE 1.7 versus 10.0 AE 1.8 m/s, P ¼ 0.25). Pravastatin has proved its efficacy in decreasing IMT in the CCA in randomized clinical trials in the general population [17] . The effect of statins on IMT in the CCA regression is related to the degree of LDL-cholesterol reduction. This effect is dose-dependent. However, the reduction in LDL-cholesterol with pravastatin seems to be lower in HIV-infected patients compared with the general population. A 20% reduction in LDL-cholesterol was observed in HIV-infected patients treated with pravastatin 40 mg a day [17] [18] [19] compared with a 30% reduction in the general population at the same dose. HIV infection by itself could lower the efficacy of pravastatin in reducing carotid atherosclerosis, as was shown with Chlamydiae pneumoniae in the general population [20] . The efficacy of more potent statins such as atorvastatin at a low dose or rosuvastatin (not metabolized by CYP 45O 3A4) on atherosclerosis may differ from that of pravastatin in dyslipidemic HIV-infected patients.
Aortic and arterial stiffness are independent predictors of cardiovascular events in the general population. We found that the influence of the duration of HIV infection on aortic stiffness was similar to that of ageing (independent of PI exposure). Like Schillaci and colleagues [21] , we found that the duration of PI exposure influenced aortic stiffness similarly to mean arterial pressure. On the other hand, in a cross-sectional study of 49 HIV-infected children compared with 24 non-HIV-infected controls, Bonnet et al. [22] found that HIV infection affected arterial stiffness, whereas no additional detrimental effects were observed after a mean of 5 years of antiretroviral therapy. In the present study, the presence of clinical lipodystrophy was associated with greater, although nonsignificant, aortic stiffness (10.08 AE 1.95 versus 9.33 AE 1.07 m/s, P ¼ 0.07). Further investigation of the vascular effects of adipocyte dysfunction and related adipocytokine disturbances in lipodystrophic HIV-infected patients is warranted [23] .
The design of this study did not permit definitive conclusions to be drawn regarding the effects of pravastatin in either treated or non-treated HIV-infected patients. However, the evaluation of carotid atherosclerosis was performed using an echotracking system with confirmed high spatial resolution, reproducibility and accuracy [15, 16] . A predefined number of patients were included to detect a clinically relevant difference in IMT in the CCA (6.5%). The two groups were appropriately matched, with similar cardiovascular risk factors including blood pressure and HIV infection parameters. The pertinent results revealed in this preliminary research merit additional investigation and confirmation by acknowledged study methods.
In this study, no impact of pravastatin therapy on carotid atherosclerosis and function in dyslipidemic HIV-infected patients receiving HAART was found. The duration of HIV infection and PI exposure were associated with increased aortic stiffness, with an impact similar to that of ageing. Randomized trials are essential to evaluate the efficacy of statins in reducing carotid atherosclerosis in HIV-infected patients.
